脂肪营养不良 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-10-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Amino acid length | 44 residues | Matches the native peptide backbone |
| Molecular weight | Approximately 5135 Da | Calculated from the peptide sequence |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
| Primary studied use | Visceral fat reduction | Investigated in HIV-associated lipodystrophy |
特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。
监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。
== Syntheses == Salts of many cyclopropenyl cations have been characterized. Their stability varies according to the steric and inductive effects of the substituents. Salts of triphenylcyclopropenium were first reported by Ronald Breslow in 1957. The salt was prepared in two steps starting with the reaction of phenyldiazoacetonitrile with diphenylacetylene to yield 1,2,3-triphenyl-3-cyclopropene nitrile. Treatment of this with boron trifluoride yielded [C3Ph3]BF4.
Evidence for the important role antithrombin plays in regulating normal blood coagulation is demonstrated by the correlation between inherited or acquired antithrombin deficiencies and an increased risk of any affected individual developing thrombotic disease. Antithrombin deficiency generally comes to light when a patient suffers recurrent venous thrombosis and pulmonary embolism.
== External links == Major Lectins & Conjugated Lectins from different natural sources Functional Glycomics Gateway, a collaboration between the Consortium for Functional Glycomics and Nature Publishing Group Proteopedia shows more than 800 three-dimensional molecular models of lectins, fragments of lectins and complexes with carbohydrates EY Laboratories, Inc., Lectin and Lectin Conjugates manufacturer Recombinant Protein Purification Handbook Archived 2008-12-05 at the Wayback Machine Immobilized lectins, chromatography media Medicago AB, Lectin and Lectin Conjugates manufacturer Con A Proteopedia 1bxh, pokeweed lectin Proteopedia 1uha, Artocarpus lectin Proteopedia 1toq, Pterocarpus lectin Proteopedia 1q8v, Urtica lectin Proteopedia 1en2
Sources: en.wikipedia.org
== Pharmacokinetics == No clinically useful absorption of colistin occurs in the gastrointestinal tract. For systemic infection, colistin must therefore be given by injection. Colistimethate is eliminated by the kidneys, but colistin is eliminated by non-renal mechanism(s) that are as of yet not characterised.
Apart from the long history, cod differ from most fish because the fishing grounds are far from population centres. The large cod fisheries along the coast of North Norway (and in particular close to the Lofoten islands) have been developed almost uniquely for export, depending on sea transport of stockfish over large distances. Since the introduction of salt, dried and salted cod (clipfish or 'klippfisk' in Norwegian) has also been exported. By the end of the 14th century, the Hanseatic League dominated trade operations and sea transport, with Bergen as the most important port. William Pitt the Elder, criticizing the Treaty of Paris in Parliament, claimed cod was "British gold"; and that it was folly to restore Newfoundland fishing rights to the French. In the 17th and 18th centuries in the New World, especially in Massachusetts and Newfoundland, cod became a major commodity, creating trade networks and cross-cultural exchanges. In 1733, Britain tried to gain control over trade between New England and the British Caribbean by imposing the Molasses Act, which they believed would eliminate the trade by making it unprofitable. The cod trade grew instead, because the "French were eager to work with the New Englanders in a lucrative contraband arrangement". In addition to increasing trade, the New England settlers organized into a "codfish aristocracy". The colonists rose up against Britain's "tariff on an import". In the 20th century, Iceland re-emerged as a fishing power and entered the Cod Wars.
Global Security Weapons and Complex Integration National Ignition Facility and Photon Science Operations and Business Business Facilities & Infrastructure Institutional Facilities Management Integrated Safety Management System Project Office Nuclear Operations Planning and Financial Management Staff Relations Strategic Human Resources Management Three other directorates are each headed by a principal associate director who reports to the LLNL director:
Sources: en.wikipedia.org
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.
The synthetic peptide incorporates modifications that slow enzymatic breakdown in circulation. Native growth hormone-releasing hormone is short-lived, whereas the analog is designed for greater stability. The core amino acid backbone is largely retained.
The main studied application is reduction of excess visceral abdominal fat in HIV-associated lipodystrophy. Research has measured fat changes through imaging. Findings concern fat distribution rather than overall body weight.
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.